Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Im Super Holdings LLC

Neither a doctor nor a teaching hospital

Research payments

$1,691,095

195 payments

Through program year 2025, Im Super Holdings LLC is reported as receiving $1,691,095 in research payments, across 195 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $640,983 95
2024 Research $586,762 68
2023 Research $450,100 30
2022 Research $13,250 2

Breakdown

Who paid Research payments · program years 2022–2025
  1. AbbVie, Inc. $474,685 101 payments
  2. Axsome Therapeutics, Inc. $331,528 27 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $292,717 3 payments
  4. Janssen Research & Development, LLC $211,711 24 payments
  5. E.R. Squibb & Sons, L.L.C. $172,700 4 payments
  6. Abbott Laboratories $85,164 6 payments
  7. Sumitomo Pharma America, Inc. $60,184 13 payments
  8. F. Hoffmann-La Roche AG $33,250 14 payments
  9. Vanda Pharmaceuticals Inc. $29,157 3 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms $331,528 27 payments
  2. Hepatic Impairment Study $289,119 2 payments
  3. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $265,259 66 payments
  4. A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $109,889 2 payments
  5. A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an $89,278 8 payments
  6. HbA1c Variation Study $81,664 5 payments
  7. A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication $52,219 9 payments
  8. A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) $51,971 7 payments
  9. M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $50,692 18 payments
  10. Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder $49,325 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record